ALK positively regulates MYCN activity through repression of HBP1 expression.
Anaplastic Lymphoma Kinase
/ genetics
Animals
Cell Line, Tumor
Cell Proliferation
/ genetics
Down-Regulation
/ genetics
Forkhead Box Protein O3
/ genetics
Gene Expression Regulation, Neoplastic
/ genetics
High Mobility Group Proteins
/ genetics
Humans
Mice
MicroRNAs
/ genetics
Mutation
/ genetics
N-Myc Proto-Oncogene Protein
/ genetics
Neuroblastoma
/ genetics
Phosphatidylinositol 3-Kinases
/ genetics
Proto-Oncogene Proteins c-akt
/ genetics
Repressor Proteins
/ genetics
Signal Transduction
/ genetics
Transcriptional Activation
/ genetics
Journal
Oncogene
ISSN: 1476-5594
Titre abrégé: Oncogene
Pays: England
ID NLM: 8711562
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
received:
16
10
2017
accepted:
23
10
2018
revised:
03
05
2018
pubmed:
13
12
2018
medline:
30
4
2019
entrez:
13
12
2018
Statut:
ppublish
Résumé
ALK mutations occur in 10% of primary neuroblastomas and represent a major target for precision treatment. In combination with MYCN amplification, ALK mutations infer an ultra-high-risk phenotype resulting in very poor patient prognosis. To open up opportunities for future precision drugging, a deeper understanding of the molecular consequences of constitutive ALK signaling and its relationship to MYCN activity in this aggressive pediatric tumor entity will be essential. We show that mutant ALK downregulates the 'HMG-box transcription factor 1' (HBP1) through the PI
Identifiants
pubmed: 30538293
doi: 10.1038/s41388-018-0595-3
pii: 10.1038/s41388-018-0595-3
doi:
Substances chimiques
Forkhead Box Protein O3
0
HBP1 protein, human
0
High Mobility Group Proteins
0
MYCN protein, human
0
MicroRNAs
0
N-Myc Proto-Oncogene Protein
0
Repressor Proteins
0
Phosphatidylinositol 3-Kinases
EC 2.7.1.-
ALK protein, human
EC 2.7.10.1
Anaplastic Lymphoma Kinase
EC 2.7.10.1
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2690-2705Références
Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3260-5
pubmed: 10737792
Oncogene. 2010 Mar 4;29(9):1394-404
pubmed: 19946337
Nat Rev Clin Oncol. 2012 May 15;9(7):391-9
pubmed: 22585002
Nat Rev Cancer. 2013 Jun;13(6):397-411
pubmed: 23702928
Curr Opin Oncol. 2015 Mar;27(2):118-24
pubmed: 25588040
Sci Rep. 2017 Aug 31;7(1):10274
pubmed: 28860499
Cancer Cell. 2014 Aug 11;26(2):262-72
pubmed: 25117713
Nature. 2008 Oct 16;455(7215):930-5
pubmed: 18724359
Cancer Res. 2016 Sep 15;76(18):5523-37
pubmed: 27635046
Blood. 2004 Jun 15;103(12):4622-9
pubmed: 14962911
Leukemia. 2005 Nov;19(11):1958-68
pubmed: 16179914
Cancer Res. 2014 Dec 1;74(23):7048-59
pubmed: 25287161
Oncogene. 2012 Dec 13;31(50):5193-200
pubmed: 22286764
Development. 2015 Jul 1;142(13):2278-90
pubmed: 26041766
Dis Model Mech. 2016 Sep 1;9(9):941-52
pubmed: 27483357
Oncol Res Treat. 2015;38(6):291-8
pubmed: 26045026
Cancer Discov. 2013 Mar;3(3):308-23
pubmed: 23430699
Cell Oncol (Dordr). 2015 Oct;38(5):341-52
pubmed: 26306783
Sci Transl Med. 2012 Jul 4;4(141):141ra91
pubmed: 22764207
Clin Cancer Res. 2015 Jul 15;21(14):3327-39
pubmed: 25805801
Nature. 2008 Oct 16;455(7215):975-8
pubmed: 18923525
Biochem J. 2014 May 15;460(1):25-34
pubmed: 24762137
Oncogene. 2006 Jan 5;25(1):130-8
pubmed: 16116477
Nature. 2008 Oct 16;455(7215):971-4
pubmed: 18923524
PLoS Comput Biol. 2014 Jul 24;10(7):e1003731
pubmed: 25058159
Cancer Cell. 2012 Jul 10;22(1):117-30
pubmed: 22789543
Cancer Res. 2009 Sep 15;69(18):7338-46
pubmed: 19723661
Genes Dev. 2006 May 1;20(9):1123-36
pubmed: 16618801
Cancer Cell. 2016 Mar 14;29(3):311-323
pubmed: 26977882
J Biol Chem. 2013 Mar 22;288(12):8332-41
pubmed: 23362253
Chem Biol. 2013 May 23;20(5):713-25
pubmed: 23706636
Genome Biol. 2007;8(2):R19
pubmed: 17291332
Genome Biol. 2003;4(10):R69
pubmed: 14519204
Oncotarget. 2014 Sep 30;5(18):8737-49
pubmed: 25228590
Proc Natl Acad Sci U S A. 2012 Nov 20;109(47):19190-5
pubmed: 23091029
Oncogene. 2015 Jun;34(26):3357-68
pubmed: 25174395
Ann N Y Acad Sci. 2005 Nov;1059:145-59
pubmed: 16382050
Front Oncol. 2015 May 12;5:111
pubmed: 26029667
Oncotarget. 2016 Sep 6;7(36):57525-57544
pubmed: 27438153
Int J Cancer. 2015 Mar 1;136(5):E252-61
pubmed: 25220031
Cancer Cell. 2012 Mar 20;21(3):362-73
pubmed: 22439933
Nature. 2008 Oct 16;455(7215):967-70
pubmed: 18923523
Sci Transl Med. 2011 Nov 9;3(108):108ra114
pubmed: 22072639
Proc Natl Acad Sci U S A. 2008 Sep 16;105(37):14094-9
pubmed: 18780787
Annu Rev Med. 2015;66:49-63
pubmed: 25386934
Nature. 2012 Feb 22;483(7391):589-93
pubmed: 22367537
Clin Cancer Res. 2014 May 1;20(9):2249-56
pubmed: 24789032
Cancer Res. 2006 Aug 15;66(16):8139-46
pubmed: 16912192
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Cancer Res. 2013 Apr 1;73(7):2189-98
pubmed: 23378341
Lancet Oncol. 2013 May;14(6):472-80
pubmed: 23598171
Cancer Cell. 2014 Nov 10;26(5):682-94
pubmed: 25517749
J Biol Chem. 2006 Apr 21;281(16):10865-75
pubmed: 16495219
Sci Signal. 2014 Oct 28;7(349):ra102
pubmed: 25351247
Cancer Cell. 2011 May 17;19(5):679-90
pubmed: 21575866
Cancer Res. 2016 Mar 15;76(6):1506-16
pubmed: 26719536
J Biol Chem. 2010 Feb 12;285(7):4847-58
pubmed: 20008325
Clin Cancer Res. 2011 Dec 1;17(23):7394-401
pubmed: 21948233
Cancer Cell. 2003 Sep;4(3):223-38
pubmed: 14522256
Breast Cancer Res Treat. 2011 Apr;126(3):565-75
pubmed: 20505989
Cell Signal. 2018 Apr;44:158-170
pubmed: 29355710
J Leukoc Biol. 2016 Apr;99(4):569-78
pubmed: 26561567
Genes Cancer. 2011 May;2(5):538-49
pubmed: 21901167
Mol Cancer Ther. 2014 Feb;13(2):454-67
pubmed: 24282277
Oncogene. 2016 Jul 14;35(28):3681-91
pubmed: 26616860
Oncotarget. 2016 Apr 26;7(17):23715-29
pubmed: 27009859
Sci Rep. 2013 Dec 20;3:3450
pubmed: 24356251
Cancer Cell. 2015 Jun 8;27(6):837-51
pubmed: 26058079
Clin Cancer Res. 2010 Sep 1;16(17):4353-62
pubmed: 20719933
Clin Cancer Res. 2016 Jun 1;22(11):2605-10
pubmed: 27250929
Cell. 2012 Apr 13;149(2):307-21
pubmed: 22500798
Genes Dev. 1997 Feb 1;11(3):383-96
pubmed: 9030690